Compare Caesars Entertainment Inc (CZR) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Caesars Entertainment Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Caesars Entertainment Inc trades at $29.49 (market cap $6.02B), while Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 2.1× Caesars Entertainment Inc's market cap, and Caesars Entertainment Inc is more actively traded (6,412,151 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Caesars Entertainment Inc for 31 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| CZR | HALO | |
|---|---|---|
Market Cap | $6.02B | $12.58B |
Volume | 6,412,151 | 2,179,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $30.41 | $115.22 |
52-Week Low | $18.14 | $61.63 |
Typical Hold Time | 31 Days | 1 Days |
Enterprise Value | $29.91B | $14.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CZR trades at $29.50, up slightly by 0.03% today, with a bearish technical signal and neutral oscillators. The company reported a net loss of $502 million in 2025, missing earnings estimates for three consecutive quarters, while revenue remains stable near $11.5 billion. A pending merger with Fertitta Entertainment at $31.00 per share is under regulatory review, with several law firms investigating the deal's fairness.
CZR faces headwinds from persistent losses and high debt, but the merger offer provides a near-term price floor. Upside depends on operational turnaround and deal approval, while risks include earnings volatility and regulatory hurdles. Analyst consensus is mixed, with a hold-heavy rating and a $30.75 price target slightly above current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
